Early outcomes of eftilagimod alpha with pembrolizumab in HNSCC treatment

Claus Andrup Kristensen, MD, PhD, Rigshospitalet, Copenhagen, Denmark, comments on findings from the TACTI-003 trial (NCT04811027) on eftilagimod alpha with pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Although results showed a higher objective response rate with the combination therapy versus pembrolizumab alone, the difference was not statistically significant. Further insights are anticipated with upcoming secondary endpoint data, including survival outcomes, to inform future use of eftilagimod alpha in HNSCC. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.